In June of 2010, KEI was informed that representatives from the the United States Food and Drug Administration (FDA) had recently attended a summit in India on the issue of counterfeited and spurious medicines organized by the Partnership for Safe Medicines (PSM), a US-based organization with clear links to pharmaceutical corporate interests.
(This timeline is part of a larger project at KEI regarding an evaluation of the 1971 Appendix to the Berne Convention on “SPECIAL PROVISIONS REGARDING DEVELOPING COUNTRIES.) In 1970, Charles F. Johnson wrote “The Origins of the Stockholm Protocol, 18… Continue Reading →
1. Recalling that the SCP was established to serve as a forum to discuss issues, facilitate coordination and provide guidance concerning the progressive international development of patent law,
KEI statement on Exclusions from Patentable Subject Matter and Exceptions and Limitations to the Rights
SCP 15
13 October 2010
Thank you Mr. Chair.
We take note of Professor Coenraad Visser’s study which examined ‘Selected Case Studies of Countries Where Compulsory Licences Have Been Granted for Pharmaceuticals’.
SCP 15
General Statement of Knowledge Ecology International
12 October 2010
Thank you Mr. Chair, and I would like to take this opportunity to congratulate you and the vice-chairs upon your re-election.
1. Knowledge Ecology International welcomes the reports by experts, thanks the Secretariat for its work on this topic.
As a general matter, KEI suggests the WIPO Secretariat provide standardized disclosure of the professional consulting that various experts do, as is the practice for other UN bodies and some academic journals.
Note: On October 8, 2010, Senator Wyden asked the American Law Division of the Congressional Research Service of the Library of Congress undertake and provide to Congress: Continue Reading →
Noting the ACTA is being negotiated as an “executive agreement” because “it is not intended to impact U.S. law, but that “some experts outside of government are raising concerns that the ACTA text is contrary to U.S. law and its application or would present a barrier to changes in U.S. Continue Reading →
The following is a summary of S. 3921, 111th Congress, the Ethical Pathway Act of 2010, provided by the Office of Senator Sanders, plus an attachment of Article 20 and 21 f the Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects.